By a News Reporter-Staff News Editor at Angiogenesis Weekly -- Investigators publish new report on Myoblasts. According to news reporting out of Seoul, South Korea, by NewsRx editors, research stated, "Peripheral arterial disease is a common manifestation of systemic atherosclerosis, which results in more serious consequences of ischemic events in peripheral tissues such as the lower extremities. Cell therapy has been tested as a treatment for peripheral ischemia that functions by inducing angiogenesis in the ischemic region."
Our news journalists obtained a quote from the research from Dongguk University, "However, the poor survival and engraftment of transplanted cells limit the efficacy of cell therapy. In order to overcome such challenges, we applied genetically engineered cell sheets using a cell-interactive and thermosensitive hydrogel and nonviral polymer nanoparticles. C2C12 myoblast sheets were formed on Tetronic-tyramine (Tet-TA)-RGD hydrogel prepared through a highly efficient and noncytotoxic enzymatic reaction. The myoblast sheets were then transfected with vascular endothelial growth factor (VEGF) plasmids using poly(beta-amino ester) nanoparticles to increase the angiogenic potential of the sheets. The transfection increased the VEGF expression and secretion from the C2C12 sheets. The enhanced angiogenic effect of the VEGF-transfected C2C12 sheets was confirmed using an in vitro capillary formation assay. More importantly, the transplantation of the VEGF-transfected C2C12 sheets promoted the formation of capillaries and arterioles in ischemic muscles, attenuated the muscle necrosis and fibrosis progressed by ischemia, and eventually prevented ischemic limb loss."
According to the news editors, the research concluded: "The combination of cell sheet engineering and genetic modification can provide more effective treatment for therapeutic angiogenesis."
For more information on this research see: Genetically Engineered Myoblast Sheet for Therapeutic Angiogenesis. Biomacromolecules, 2014;15(1):361-372. Biomacromolecules can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; Biomacromolecules - www.pubs.acs.org/journal/bomaf6)
Our news journalists report that additional information may be obtained by contacting J. Lee, Dongguk Univ Seoul, Dept. of Chem & Biochem Engn, Seoul 100715, South Korea. Additional authors for this research include I. Jun, H.J. Park, T.J. Kang, H. Shin and S.W. Cho (see also Myoblasts).
Keywords for this news article include: Asia, Biotechnology, Seoul, Myoblasts, Treatment, South Korea, Cell Therapy, Nanoparticle, Bioengineering, Nanotechnology, Biological Therapy, Genetic Engineering, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC